» Articles » PMID: 38890455

Digital Spatial Profiling of the Microenvironment of Muscle Invasive Bladder Cancer

Overview
Journal Commun Biol
Specialty Biology
Date 2024 Jun 18
PMID 38890455
Authors
Affiliations
Soon will be listed here.
Abstract

Muscle invasive bladder cancer (MIBC) is a molecularly diverse disease with varied clinical outcomes. Molecular studies typically employ bulk sequencing analysis, giving a transcriptomic snapshot of a section of the tumour. However, tumour tissues are not homogeneous, but are composed of distinct compartments such as the tumour and stroma. To investigate the molecular profiles of bladder cancer, whilst also maintaining the spatial complexity of the tumours, we employed whole transcriptome Digital Spatial Profiling (DSP). With this method we generated a dataset of transcriptomic profiles of tumour epithelium, stroma, and immune infiltrate. With these data we investigate the spatial relationship of molecular subtype signatures and ligand signalling events. We find that Basal/Squamous and Classical subtypes are mostly restricted to tumour regions, while the stroma-rich subtype signatures are abundant within the stroma itself. Additionally, we identify ligand signalling events occurring between tumour, stroma, and immune infiltrate regions, such as immune infiltrate derived GPNMB, which was highly correlated with VEGFA expression within the tumour. These findings give us new insights into the diversity of MIBC at a molecular level and provide a dataset with detailed spatial information that was not available before in bladder cancer research.

Citing Articles

Single-cell RNA sequencing and spatial transcriptome analysis in bladder cancer: Current status and future perspectives.

Yoshihara K, Ito K, Kimura T, Yamamoto Y, Urabe F Bladder Cancer. 2025; 11(1):23523735251322017.

PMID: 40034247 PMC: 11864234. DOI: 10.1177/23523735251322017.


Sarcomatoid areas of urothelial carcinoma are enriched for CD163-positive antigen-presenting cells.

Johnson 3rd B, Parimi V, Kamanda S, Corney D, Choi W, Hoffman-Censits J J Pathol Clin Res. 2025; 11(2):e70021.

PMID: 39971624 PMC: 11839278. DOI: 10.1002/2056-4538.70021.


Evaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional Series.

Rahman S, Kong V, Jalfon M, Hesse D, Kim J, Wright J Cancers (Basel). 2024; 16(17).

PMID: 39272908 PMC: 11394101. DOI: 10.3390/cancers16173050.

References
1.
Lee H, Chung W, Lee H, Jeong D, Jo A, Lim J . Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient. Genome Med. 2020; 12(1):47. PMC: 7251908. DOI: 10.1186/s13073-020-00741-6. View

2.
Huang Y, Chu P, Chen J, Huang C, Huang C, Tsai Y . Expression pattern and prognostic impact of glycoprotein non-metastatic B (GPNMB) in triple-negative breast cancer. Sci Rep. 2021; 11(1):12171. PMC: 8190094. DOI: 10.1038/s41598-021-91588-3. View

3.
De Filippis R, Wolflein G, Um I, Caie P, Warren S, White A . Use of High-Plex Data Reveals Novel Insights into the Tumour Microenvironment of Clear Cell Renal Cell Carcinoma. Cancers (Basel). 2022; 14(21). PMC: 9658714. DOI: 10.3390/cancers14215387. View

4.
Fu H, Zhu Y, Wang Y, Liu Z, Zhang J, Xie H . Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer. Clin Cancer Res. 2018; 24(13):3069-3078. DOI: 10.1158/1078-0432.CCR-17-2687. View

5.
Rao A, Barkley D, Franca G, Yanai I . Exploring tissue architecture using spatial transcriptomics. Nature. 2021; 596(7871):211-220. PMC: 8475179. DOI: 10.1038/s41586-021-03634-9. View